Kar Lin
Medical · Smyrna, GANPI 1821714908
Payments from drug & device makers
Across 171 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$857
- AbbVie$460
- AstraZeneca$418
- Pfizer$264
- Lilly USA, LLC$240
- GSK$217
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,680100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $857 |
| AbbVie | 17 | $460 |
| AstraZeneca | 20 | $418 |
| Pfizer | 12 | $264 |
| Lilly USA, LLC | 13 | $240 |
| GSK | 7 | $217 |
| Idorsia Pharmaceuticals US Inc | 9 | $186 |
| Shield Therapeutics Inc | 6 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Axsome Therapeutics, Inc. | 5 | $130 |
| Bayer | 6 | $126 |
| Exact Sciences | 5 | $98 |
| Amgen | 3 | $53 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Novartis | 2 | $40 |
| Dexcom, Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Merck | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$3,680 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 12 | $6,966 |
| Atorvastatin Calcium | 69 | $589 |
| Levothyroxine Sodium | 43 | $440 |
| Hydroxyzine Hcl | 25 | $407 |
| Pravastatin Sodium | 16 | $305 |
| Glipizide | 12 | $269 |
| Gabapentin | 21 | $241 |
| Rosuvastatin Calcium | 26 | $230 |
| Losartan Potassium | 51 | $213 |
| Amlodipine Besylate | 44 | $201 |
| Zolpidem Tartrate | 15 | $196 |
| Potassium Chloride | 15 | $143 |
| Metoprolol Tartrate | 16 | $136 |
| Simvastatin | 18 | $109 |
| Pantoprazole Sodium | 11 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $20 | $6,96612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.
Other medical in Smyrna
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.